<DOC>
	<DOCNO>NCT02728115</DOCNO>
	<brief_summary>Cellavita HD stem-cell therapy Huntington 's Disease . This first-in-human , dose escalation study participant Huntington 's Disease receive 3 intravenous injection follow 5 year evaluate safety preliminary evidence effectiveness .</brief_summary>
	<brief_title>Safety Evaluation Cellavita HD Administered Intravenously Participants With Huntington 's Disease</brief_title>
	<detailed_description>This first-in-human , dose escalation , non-randomized phase I study participant HD receive 3 intravenous injection one three dose investigational product , one every month three month . Safety evaluation data include report adverse event ( include type , frequency , intensity , seriousness , severity , action take related investigational product study ) , change vital sign , physical examination medical evaluation , change laboratory test serology electrocardiogram ( ECG ) , incidence classification benign malignant neoplasm . Clinical improvement motor , cognitive behavioral degradation assess follow parameter : inflammatory marker : IL-2 , IL-4 , IL-6 , IL-10 ( interleukin IL ) e TNF-alpha ( tumoral necrosis factor alpha ) ; application UHDRS Scale ( Unified Huntington 's Disease Rating Scale ) ; BMI assessment ( Body Mass Index ) ; CNS assess magnetic resonance .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Sign date ICF ; Male participant age ≥ 21 ≤ 65 ; Participants submit medical report ( PCR ) attest Huntington 's disease number CAG repeat chromosome 4 , great equal 40 less equal 50 ( participant perform examination and/or report available , new exam do ) ; Score 5 point motor assessment UHDRS scale ( Unified Huntington 's Disease Rating Scale ) time enrollment ; Score 8 11 point functional capacity UHDRS scale time enrollment . Participation within 12 month clinical trial ; Juvenile Huntington disease diagnosis ; History epilepsy ; Diagnostic major cognitive impairment ; Active decompensated psychiatric disease ; Current prior history neoplasia ; Current history gastrointestinal , hepatic , renal , endocrine , pulmonary , hematologic , immune , metabolic pathology severe uncontrolled cardiovascular disease ; Diagnostic active infection , viral , bacterial , fungal , cause another pathogen ; Participants contraindication undergo test perform study , example , pacemaker surgical clip ; History alcohol illegal drug abuser ; Active smoker stop smoke less six month prior enrollment ; Test positive least one serological test : HIV 1 2 ( AntiHIV1,2 ) , HTLV I II , HBV ( HBsAg , antiHBc ) , HCV ( antiHCVAb ) VDRL ( Treponema pallidum ) ; History drug allergy , include contrast image , bovine product ; In use expect use immunosuppressive drug prohibit medicine first three month first administration investigational product ; Any clinical change interpret medical researcher risk participant 's enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Huntington 's Disease</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Dental Pulp Stem Cells</keyword>
</DOC>